TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06408116

Intervention type: RADIATION
Group type: OTHER
Intervention: photon
Description: radiation with 4-5 cm safte margin

Intervention type: PROCEDURE
Group type: OTHER
Intervention: surgical therapy
Description: surgery based on PET-CT/MRI staging

Intervention type: PROCEDURE
Group type: OTHER
Intervention: surgical therapy
Description: surgery based on PET-CT/MRI staging

Intervention type: PROCEDURE
Group type: OTHER
Intervention: surgical therapy
Description: surgery based on PET-CT/MRI staging

Intervention type: DRUG
Group type: OTHER
Intervention: Chemotherapy
Description: neoadjuvant chemotherapy

Intervention type: DRUG
Group type: OTHER
Intervention: Chemotherapy
Description: neoadjuvant chemotherapy
Study: NCT05459493

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TJAOA101
Description: Once enrolled, participants will be administrated TJAOA101
Study: NCT05869929

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vegetables
Description: 4-5 servings of vegetables daily, per USDA guidelines.
Study: NCT05305599

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZED1227
Description: ZED1227 is a peptidomimetic designed to inhibit the activity of human tissue transglutaminase 2 (TG2).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZED1227
Description: ZED1227 is a peptidomimetic designed to inhibit the activity of human tissue transglutaminase 2 (TG2).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZED1227
Description: ZED1227 is a peptidomimetic designed to inhibit the activity of human tissue transglutaminase 2 (TG2).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05118594

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pre-treatment psychotherapy recommendations
Description: After patients complete an intake evaluation and prior to starting therapy, the assigned therapist will receive automatized feedback that consists of recommendations regarding the most suitable interventions (i.e., cognitive, behavioral, interpersonal or patient-centered) for each individual patients, based on patients' baseline characteristics and a machine learning algorithm developed in a previous study. Besides the interventions recommended, therapist will receive within the system guideline and tutorial videos showing how to deliver adequately the specific interventions recommended.
Study: NCT06278675

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture needles
Description: 1. Experimental group: Sterile stainless steel needle electroacupuncture treatment was applied, and the acupuncture points were as follows: bilateral Zusanli (ST36), Neiguan (PC6), Hegu (LI4), Shaoshang (LU11), and Feng Long (ST40). 1 time a day, 30 minutes each time, for 7 days.~2. Control group: Placebo needles were applied, and the acupuncture points were as follows: bilateral Zusanli (ST36), Neiguan (PC6), Hegu (LI4), Shaoshang (LU11), and Feng Long (ST40). 1 time a day, 30 minutes each time, for 7 days.
Study: NCT06021392

Intervention type: PROCEDURE
Intervention: Z plasty and minimal excision of pilonidal sinus
Description: The investigators will perform a  Z plasty  procedure and Minimal excision procedure for patients complaining of pilonidal sinus and the investigators will compare the outcomes and rate of recurrence of these two procedures
Study: NCT06289959

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: cfDNA
Description: After achieving complete metabolic remission (Lugano response assessment criteria) following 6 cycles of R-CHOP-like chemotherapy, patients undergo plasma cfDNA testing upon enrollment，and the follow-up treatment plans are based on cfDNA results.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: cfDNA
Description: After achieving complete metabolic remission (Lugano response assessment criteria) following 6 cycles of R-CHOP-like chemotherapy, patients undergo plasma cfDNA testing upon enrollment，and the follow-up treatment plans are based on cfDNA results.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: cfDNA
Description: After achieving complete metabolic remission (Lugano response assessment criteria) following 6 cycles of R-CHOP-like chemotherapy, patients undergo plasma cfDNA testing upon enrollment，and the follow-up treatment plans are based on cfDNA results.
Study: NCT05928650

Intervention type: OTHER
Intervention: Evaluation of menstrual function
Description: Evaluation of serum estradiol levels and menstrual history characteristics between sprinters, long marathon runners and non-athletes.

Intervention type: OTHER
Intervention: Evaluation of menstrual function
Description: Evaluation of serum estradiol levels and menstrual history characteristics between sprinters, long marathon runners and non-athletes.

Intervention type: OTHER
Intervention: Evaluation of menstrual function
Description: Evaluation of serum estradiol levels and menstrual history characteristics between sprinters, long marathon runners and non-athletes.
Study: NCT05274386

Intervention type: DEVICE
Group type: OTHER
Intervention: Fabian ventilator with PRICO system (Acutronic Medical Systems AG, Hirzel, Switzerland); SpO2 averaging time set to 4to6 s
Description: The SpO2 averaging time will be set to 4to6 s for the next 12 hours.

Intervention type: DEVICE
Group type: OTHER
Intervention: Fabian ventilator with PRICO system (Acutronic Medical Systems AG, Hirzel, Switzerland); SpO2 averaging time set to 10 s
Description: The SpO2 averaging time will be set to 10 s for the next 12 hours.

Intervention type: DEVICE
Group type: OTHER
Intervention: Fabian ventilator with PRICO system (Acutronic Medical Systems AG, Hirzel, Switzerland); SpO2 averaging time set to 16 s
Description: The SpO2 averaging time will be set to 16 s for the next 12 hours.
Study: NCT05996250

Intervention type: OTHER
Group type: OTHER
Intervention: Immersive virtual reality task
Description: participants will have to wear a virtual reality headset connected to a remote control and will have to perform submersive virtual reality tasks
Study: NCT04766749

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RIPC
Description: RIPC is delivered with a standard blood pressure cuff placed on the upper thigh. The cuffs are inflated to 200 mm Hg and keep inflated for 5 minutes,Then deflated to 0 mmHg and keep uninflated for 5 minutes, This cycle is repeated four times
Study: NCT03534102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Improved Opioid-Tapering Instructions
Description: Applied to first and second experimental groups in the form of discharge instructions and directions from nursing staff.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Improved Opioid-Tapering Instructions
Description: Applied to first and second experimental groups in the form of discharge instructions and directions from nursing staff.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinical Patient Educator
Description: Applied to second experimental group in the form of regular calls about weaning off narcotic medications.
Study: NCT05635929

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Composition comprising olive oil, xylitol and betaine
Description: Topical composition in the form of a gel.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Composition comprising olive oil, xylitol and betaine
Description: Topical composition in the form of a gel.
Study: NCT06515925

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Our Whole Lives (OWL)
Description: OWL is a nine-session, web-accessible, self-paced mindfulness curriculum that has interactive components of self-monitoring and social support (online community). Our Whole Lives (OWL) online curriculum of self-management topics such as mindfulness, mind-body practices, education about chronic pain therapies, stress reduction, sleep, and nutrition.~Once a week for 9 weeks participants will attend a 1.5 -2-hour online group session via Zoom or Google Meets, accessing it through GEMINI platform.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low Dose Mindfulness Training
Description: The GEMINI platform will facilitate the delivery of a low-dose version of Our Whole Lives program. OWL in this arm is a nine-session, web-accessible, self-paced curriculum, self-monitoring. Participants will interface with the GEMINI platform's static content.
Study: NCT06566573

Intervention type: OTHER
Group type: OTHER
Intervention: Pain
Description: The relationship between the degree of stenosis and pain in patients with lumbar spinal stenosis will be evaluated with a visual analogue scale.

Intervention type: OTHER
Group type: OTHER
Intervention: Pain
Description: The relationship between the degree of stenosis and pain in patients with lumbar spinal stenosis will be evaluated with a visual analogue scale.

Intervention type: OTHER
Group type: OTHER
Intervention: Pain
Description: The relationship between the degree of stenosis and pain in patients with lumbar spinal stenosis will be evaluated with a visual analogue scale.

Intervention type: OTHER
Group type: OTHER
Intervention: Pain
Description: The relationship between the degree of stenosis and pain in patients with lumbar spinal stenosis will be evaluated with a visual analogue scale.

Intervention type: OTHER
Group type: OTHER
Intervention: Normal Range of Motion
Description: CROM will be used for normal range of motion (ROM) of the cervical region. Measurements will be made separately for flexion, extension, right rotation, left rotation, right and left lateral flexion.

Intervention type: OTHER
Group type: OTHER
Intervention: Normal Range of Motion
Description: CROM will be used for normal range of motion (ROM) of the cervical region. Measurements will be made separately for flexion, extension, right rotation, left rotation, right and left lateral flexion.

Intervention type: OTHER
Group type: OTHER
Intervention: Normal Range of Motion
Description: CROM will be used for normal range of motion (ROM) of the cervical region. Measurements will be made separately for flexion, extension, right rotation, left rotation, right and left lateral flexion.

Intervention type: OTHER
Group type: OTHER
Intervention: Normal Range of Motion
Description: CROM will be used for normal range of motion (ROM) of the cervical region. Measurements will be made separately for flexion, extension, right rotation, left rotation, right and left lateral flexion.

Intervention type: OTHER
Group type: OTHER
Intervention: Proprioceptive Sense
Description: CROM will be used for cervical proprioception. Measurements will be made separately for flexion, extension, right rotation, left rotation, right and left lateral flexion.

Intervention type: OTHER
Group type: OTHER
Intervention: Proprioceptive Sense
Description: CROM will be used for cervical proprioception. Measurements will be made separately for flexion, extension, right rotation, left rotation, right and left lateral flexion.

Intervention type: OTHER
Group type: OTHER
Intervention: Proprioceptive Sense
Description: CROM will be used for cervical proprioception. Measurements will be made separately for flexion, extension, right rotation, left rotation, right and left lateral flexion.

Intervention type: OTHER
Group type: OTHER
Intervention: Proprioceptive Sense
Description: CROM will be used for cervical proprioception. Measurements will be made separately for flexion, extension, right rotation, left rotation, right and left lateral flexion.
Study: NCT06564961

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clomiphene Citrate
Description: 50 mg tab once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 tab once daily
Study: NCT06541561

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcutaneous electrical acupoint stimulation
Description: Patients who meet the enrollment criteria will be randomized 1:1 to either the transcutaneous electrical acupoint stimulation (TEAS) or the sham groups. In the TEAS group, the acupoints are bilateral neiguan (PC6) and Zusanli(ST 36) acupoints.~Patients will receive 30min TEAS before anesthesia until be discharged from the post anaesthesia care unit (PACU). The same treatment for 30 min will be performed on the 1st, 2nd and 3rd days after surgery. The stimulation intensity will be adjusted in accordance with the maximal level tolerated by each patient.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham transcutaneous electrical acupoint stimulation
Description: Patients in the sham group will receive electrode attachment but without stimulation.
Study: NCT05125822

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meal replacement and lifestyle modification
Description: Meal replacement and lifestyle modification
Study: NCT06561620

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Befotertinib
Description: Befotertinib is a novel, selective oral third-generation epidermal growth factor receptor tyrosine-kinase inhibitor.
Study: NCT06023940

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High fiber
Description: A pea fiber supplement is added to a diet of regular foods. Participants receive 25g fiber daily.
Study: NCT06381115

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SleepWell24 Application
Description: The SleepWell24 application will use connections with a Shelly smart plug and a Fitbit Charge 4 along with weekly questionnaires to monitor CPAP usage.
Study: NCT06344858

Intervention type: DRUG
Intervention: Ketamine
Description: One bolus of ketammine
Study: NCT04501159

Intervention type: OTHER
Intervention: blood sample pre, during and post HD
Description: Assessment of ABG pre, during and post HD

Intervention type: DEVICE
Intervention: Non invasive cardiac output assessment
Description: Four ECG style electrodes are placed on the thorax which indirectly measures cardiac output.
Study: NCT06249035

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Transoesophageal echocardiography (TEE)
Description: TEE is a diagnostic modality in which an ultrasound probe is inserted via the oesophagus in order to visualize the heart.
Study: NCT06506669

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Oral sedation
Description: Oral medication for anxiolysis administered in the preoperative setting

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo pill with no active ingredients administered in the preoperative setting
Study: NCT05692570

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBI-200 Tablet
Description: PBI-200 is a TRK inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir Oral Tablet
Description: Ritonavir is a potent CYP3A inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobicistat Oral Tablet
Description: Cobicistat is a potent CYP3A inhibitor
Study: NCT04054934

Intervention type: BEHAVIORAL
Intervention: Reversed Circadian Rhythm
Description: Revered day/ night sleep cycle

Intervention type: BEHAVIORAL
Intervention: Normal Circadian Rhythm
Description: Normal day/ night sleep cycle
Study: NCT06541756

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fibrine Clot-augmented Meniscal Repair
Description: The fibrin clot will be prepared from 50cc of bone marrow aspirate obtained from the iliac crest and mixed for 15 minutes. The fibrin clot will be shaped into a cylindrical form and compressed between the torn edges of the meniscus using a trocar system, then secured with sutures.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Meniscal Repair
Description: Patients in the standard repair group will undergo routine meniscus repair surgery using arthroscopic all-inside or inside-out sutures.
Study: NCT06575348

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: YouControl-A-Fib mHealth Application
Description: Participants will use the app for 3 months, includes 1 month phone call with Health Coach
Study: NCT06152653

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: n-acetylcystine (NAC)+ albuterol
Description: NAC is a mucolytic drug and Albuterol is a bronchodilator.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: n-acetylcystine (NAC)+ albuterol
Description: NAC is a mucolytic drug and Albuterol is a bronchodilator.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AeroEclipse-VersaPAP System
Description: The AeroEclipse-VersaPAP System combine continuous positive inspiratory pressure and nebulizer in one system.
Study: NCT05294679

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Propofol
Description: All patients completed pre-anaesthesia assessment, signed informed consent, and completed vital signs on the day before surgery, with values as baseline vital signs. On the day of surgery, after routine preparation before colonoscopy (fasting for at least 6h and water restriction for at least 2h before surgery), venous access was established in the left hand. 0.5μg/kg fentanyl was administered intravenously after oxygen inhalation through a nasal catheter (4-6 L/min). About 3 minutes after fentanyl administration, sedation induction was performed with ciprofol or propofol immediately.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofol
Description: Ciprofol
Study: NCT05579431

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-634
Description: Suspension for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-634
Description: Suspension for oral administration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Suspension for oral administration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Suspension for oral administration.
Study: NCT04914234

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atenolol Succinate Oral Tablet
Description: Atenolol 50 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoprolol Succinate Oral Tablet
Description: Metoprolol 100 mg
Study: NCT05254041

Intervention type: OTHER
Group type: OTHER
Intervention: Menstrual Cup Removal
Description: Participants will be asked to remove Menstrual cup by breaking the seal.
Study: NCT05309993

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PTNS
Description: See arm description

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TENS
Description: See arm description
Study: NCT06550440

Intervention type: BEHAVIORAL
Intervention: family integrated care
Description: Trained NICU nurses give effective education to parents of children, and regard parents as a part of NICU team, so that they can actively provide positive care for babies instead of passive caregivers. Parents mainly participate in nursing care such as bottle feeding, changing diapers, skin contact and so on.

Intervention type: BEHAVIORAL
Intervention: family integrated care
Description: Trained NICU nurses give effective education to parents of children, and regard parents as a part of NICU team, so that they can actively provide positive care for babies instead of passive caregivers. Parents mainly participate in nursing care such as bottle feeding, changing diapers, skin contact and so on.
Study: NCT05153629

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TENS
Description: TENS device used four times a day for 60 minutes each time
Study: NCT05743244

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abrocitinib 200 MG Oral Tablet
Description: Abrocitinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritlecitinib
Description: Ritlecitinib

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for Abrocitinib or Ritlecitinib
Study: NCT04758715

Intervention type: OTHER
Group type: OTHER
Intervention: Food provided from a commercial meal service provider for a week
Description: Meals from a commercial meal service provider provide for a week to participant
Study: NCT06647966

Intervention type: DIAGNOSTIC_TEST
Intervention: PET/CT
Description: \[11C\]CH PET/CT
Study: NCT06650111

Intervention type: OTHER
Intervention: Rereading of biopsies
Description: Rereading of biopsies, blinded to the final diagnosis, by a pathologist specializing in nephropathology. This review includes: an optical microscopy study on a fragment fixed with routine staining, an optical microscopy study on a frozen fragment, an immunohistochemical study on a frozen fragment if available.

Intervention type: OTHER
Intervention: Collection of data from the patient's medical file
Description: Collection of data from the patient's medical file. The clinical data of the care of patients at whom the biopsies belong will be analyzed until the date of the patient's last follow-up (before 12/31/2021).
Study: NCT06652581

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Modified Thorachoabdominal Nerve Block Perichondrial Approach(M-TAPA
Description: USG Guided Bilateral Modified Thorachoabdominal Nerve Block Perichondrial Approach (M-TAPA) using 20 ml Bupivacaine 0,25%.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Opioid Intravena
Description: Opioid Intravenous post Surgery without M-TAPA Block delivered with PCA Machine
Study: NCT06652906

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium phosphate powder
Description: After admission, the patient underwent comprehensive renal function and electrolyte tests. The first medication was taken at 7pm the day before the examination. One bag of sodium phosphate powder was diluted with 800ml or more of warm and cool water before taking. The second dose of medication should be taken at 7am on the day of operation or examination (or at least 3 hours before the examination), with the same usage as the first dose, with a 12 hour interval between each dose. The standard dose for each dose is 1 bag, until clear water like stool appears.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Polyethylene glycol electrolyte dispersion
Description: After admission, the patient underwent comprehensive renal function and electrolyte examination. The evening before the intestinal examination, 2000ml of polyethylene glycol electrolyte San III isotonic solution was taken, 250ml every 10-15 minutes, and it was taken within 2 hours. On the day of examination, 2000ml of polyethylene glycol electrolyte San III isotonic solution was taken 3-4 hours in advance until clear water like stool appeared.
Study: NCT04723329

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-based exercise training based on the transtheoretic model
Description: Motivating interviews will be provided to the patients to receive training on the website by contacting them one-on-one. In the following 1st and 3rd months, patients will be contacted individually again to confirm whether they follow the website, and they will be asked to fill in the scales on the website by providing consultancy on the issues they need. In the 6th month, the final test data will be obtained from the website using the same data collection forms.
Study: NCT06108973

Intervention type: DEVICE
Intervention: Capnography
Description: To know the Co2 graph in COPD and Normal patients under General Anesthesia

Intervention type: DEVICE
Intervention: Capnography
Description: To know the Co2 graph in COPD and Normal patients under General Anesthesia
Study: NCT06377774

Intervention type: OTHER
Intervention: No intervention in this study
Description: No intervention in this study